RPS6KA2 Antibodies

Ribosomal protein S6 kinase alpha-2 (RPS6KA2)

Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of transcription factors, regulates translation, and mediates cellular proliferation, survival, and differentiation. May function as tumor suppressor in epithelial ovarian cancer cells.

.

Gene Information

Human
Gene Name:	RPS6KA2
Uniprot:	Q15349
Entrez:	6196

Family

Belongs to:
protein kinase superfamily

Alternative Names

EC 2.7.11; EC 2.7.11.1; HU-2; MAP kinase-activated protein kinase 1c; MAPK-activated protein kinase 1c; MAPKAP kinase 1c; MAPKAPK1C; MAPKAPK-1c; p90-RSK 2; p90RSK2; p90-RSK3; ribosomal protein S6 kinase alpha 2; ribosomal protein S6 kinase alpha-2; ribosomal protein S6 kinase, 90kD, polypeptide 2; ribosomal protein S6 kinase, 90kDa, polypeptide 2; Ribosomal S6 kinase 3,90 kDa ribosomal protein S6 kinase 2; RPS6KA2; RSK; RSK3; RSK-3; RSK3pp90RSK3; S6K-alpha; S6K-alpha2; S6K-alpha-2

Molecular Weight

Mass (kDA):
83.239 kDA

Genomic Context

Human
Location:	6q27
Sequence:	6; NC_000006.12 (166409364..166862525, complement)

Tissue Specificity

Widely expressed with higher expression in lung, skeletal muscle, brain, uterus, ovary, thyroid and prostate.

Subcellular Localizations

Nucleus. Cytoplasm.

Diseases

• Malignant Neoplasms
• Neoplasms
• Malignant Neoplasm Of Breast
• Malignant Tumor Of Colon
• Mammary Neoplasms
• Rectal Carcinoma
• Inflammation
• Cholangiocarcinoma
• Colonic Neoplasms
• Pleural Neoplasms
• Carcinogenesis
• Immunologic Deficiency Syndromes

• Insulin Resistance
• Neoplasms, Glandular And Epithelial
• Tumor Angiogenesis
• Severe Combined Immunodeficiency
• Malignant Neoplasm Of Ovary
• Epithelial Ovarian Cancer
• Colorectal Cancer

Interacting Proteins

• BRAF
• MAPK1
• MAPK3
• PRKCE
• SCRIB

• SHANK1

Pathways

• Cell Growth
• Energy Homeostasis
• Cell Proliferation
• Cell Cycle
• Angiogenesis
• Regulation Of Gene Expression
• Ovulation
• Regulation Of Cell Growth

• Pathogenesis
• Localization

PTMs

• Phosphorylation

Research Areas

• Protein Kinase

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/RPS6KA2

Best Uses Of The RPS6KA2 Marker

There are many different ways to use the RPS6KA2Marker. This article focuses on two methods that use RPS6KA2 markers. First, consider the use RPS6KA2 markers in biological tests. Both methods have their benefits. The following sections provide information about how to use the RPS6KA2 mark. These sections will also provide valuable information about how these assays are used in the laboratory.

Biological assays using RPS6KA2 markers

Several biomarkers for the cancer gene RPS6KA2 have been developed, with the nominated site of LATS2 being a candidate for further validation. One such candidate for validation is the phosphopeptide, D(pS),LQK. The LATS2 pS380 site hosts the tryptic, peptide-form D(pS).LQK. This peptide type was chosen as the phosphopeptide. Eight other short phosphopeptides weren't detected in the discovery data, so they were discarded.

The SigPath is another promising candidate. This assay measures 284 phosphosites over 200 phosphoproteins within human cancer tumors. Its application in tumor models, preclinical models, and human cancer cell lines has demonstrated its utility. SigPath assays can identify large numbers of differentially-regulated phosphosites associated with cancer and disease, and can be used to nominate mechanistic hypotheses.

These markers can be used for biological assays

The RPS6KA2 protein encoded by the RPS6KA2 genes is an important protein. It has been implicated with many processes that impact human health. It is necessary for proper functioning the insulin-secreting endocrinesystem by regulating PI3K/Akt/mTor. It is important to note that the gene's promoter DNA status is linked with the levels of methyltransases. This is an important factor in the regulation insulin.

In our previous studies, we have identified eight gene loci and 10 differentially methylated CpG sites in human cell lines. Ten of these sites were significantly different between obese controls and lean ones. After correcting for false discoveries rates, we adjusted our model for cell composition. We also fixed batch effects. Our data revealed nine CpG locations that were significant were located within 8 or near gene loci. These sites were associated to the SBNO2 promor region.